Literature DB >> 10457034

How should Helicobacter pylori negative patients be managed?

V Stanghellini1, C Tosetti, R De Giorgio, G Barbara, B Salvioli, R Corinaldesi.   

Abstract

Dyspepsia is a digestive syndrome distinct from (although frequently overlapping with) gastro-oesophageal reflux disease (GORD) and irritable bowel syndrome (IBS), which is characterised by various combinations of painful and non-painful symptoms arising from the epigastrium. Dyspepsia can be secondary to a variety of diseases, but in most instances it is idiopathic. Helicobacter pylori infection is responsible for the majority of peptic ulcers and of other diseases potentially associated with dyspepsia. Nevertheless, a causal role for H pylori infection in symptom occurrence has not been established. Experimental data indicate that H pylori eradication does not improve symptoms in the majority of dyspeptic patients. It has been proposed recently that H pylori negative patients should be managed according to their clinical presentation. Some reports suggest that taking into consideration the most relevant or "predominant" symptom may help to identify distinct subgroups among dyspeptic patients with different underlying pathophysiological abnormalities and different responses to treatment. Well designed and conducted prospective studies are needed to verify whether treatment of H pylori negative dyspeptic patients based on the predominant symptom actually is a cost effective approach.

Entities:  

Mesh:

Year:  1999        PMID: 10457034      PMCID: PMC1766660          DOI: 10.1136/gut.45.2008.i32

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Management of dyspepsia: report of a working party.

Authors: 
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

Review 2.  Role of visceral afferent mechanisms in functional bowel disorders.

Authors:  E A Mayer; H E Raybould
Journal:  Gastroenterology       Date:  1990-12       Impact factor: 22.682

3.  Early detection of gastric cancer.

Authors:  M T Hallissey; W H Allum; A J Jewkes; D J Ellis; J W Fielding
Journal:  BMJ       Date:  1990-09-15

4.  Campylobacter pylori is not associated with gastroparesis.

Authors:  J L Barnett; E M Behler; H D Appelman; G H Elta
Journal:  Dig Dis Sci       Date:  1989-11       Impact factor: 3.199

5.  Screening dyspepsia by serology to Helicobacter pylori.

Authors:  G M Sobala; J E Crabtree; J A Pentith; B J Rathbone; T M Shallcross; J I Wyatt; M F Dixon; R V Heatley; A T Axon
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

6.  Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia.

Authors:  V Stanghellini; C Ghidini; M R Maccarini; G F Paparo; R Corinaldesi; L Barbara
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

7.  Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome.

Authors:  M Lémann; J P Dederding; B Flourié; C Franchisseur; J C Rambaud; R Jian
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

8.  Prevalence of symptoms of dyspepsia in the community.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1989-01-07

9.  Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia.

Authors:  A Tucci; R Corinaldesi; V Stanghellini; C Tosetti; G Di Febo; G F Paparo; O Varoli; G M Paganelli; A M Labate; C Masci
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

10.  Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride.

Authors:  R Jian; F Ducrot; A Ruskone; S Chaussade; J C Rambaud; R Modigliani; J D Rain; J J Bernier
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

View more
  1 in total

1.  The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.

Authors:  N J Talley; K Lauritsen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.